Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland.
Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, California.
J Am Soc Cytopathol. 2020 Jul-Aug;9(4):221-231. doi: 10.1016/j.jasc.2020.04.008. Epub 2020 Apr 28.
Primary thyroid gland malignant teratomas are extremely rare and can pose diagnostic challenges on fine needle aspiration (FNA) due to their cytomorphologic heterogeneity. Recent next generation sequencing studies have identified recurrent DICER1 hotspot mutations in these tumors, suggesting that malignant teratomas of the thyroid should be considered a distinct pathological entity. Herein, we review the clinico-radiologic and FNA findings in a series of DICER1 mutated malignant teratomas.
We performed a retrospective case review of 9 FNAs from 5 patients with a histologically confirmed malignant teratoma of the thyroid gland from 2 large tertiary care pathology practices.
The patients included 4 females and 1 male, with an average age of 43 years (22-65 years). The nodules were centered within the thyroid gland and ranged from 1.7 to 10 cm in diameter. FNAs of primary thyroid teratomas demonstrate marked cellularity, epithelial proliferations, an absence of colloid, and a predominance of immature spindled cells, representing the mesenchymal and neural ectodermal components of these tumors. The FNA interpretations ranged from atypia of undetermined significance to overtly malignant. Three patients died of their disease and 2 are alive with no evidence of disease.
Malignant thyroid teratoma is a rare entity with cytomorphologic overlap with other high-grade neoplasms of the thyroid. Recent molecular studies have defined recurrent DICER1 mutations in malignant thyroid teratomas and propose these as a distinct clinicopathological entity. The features described here may be helpful in providing a correct prospective interpretation.
原发性甲状腺恶性畸胎瘤极为罕见,由于其细胞形态学的异质性,在细针穿刺(FNA)中可能会带来诊断上的挑战。最近的下一代测序研究已经在这些肿瘤中发现了 DICER1 热点突变的反复出现,表明甲状腺的恶性畸胎瘤应被视为一种独特的病理实体。在此,我们回顾了一系列 DICER1 突变的恶性畸胎瘤的临床-放射学和 FNA 发现。
我们对来自 2 个大型三级护理病理学实践的 5 例经组织学证实的甲状腺恶性畸胎瘤的 9 例 FNA 进行了回顾性病例复习。
患者包括 4 名女性和 1 名男性,平均年龄为 43 岁(22-65 岁)。结节位于甲状腺内,直径从 1.7 到 10 厘米不等。原发性甲状腺畸胎瘤的 FNA 表现为明显的细胞增多症、上皮增生、无胶体以及幼稚梭形细胞为主,代表这些肿瘤的间充质和神经外胚层成分。FNA 诊断结果从意义未明的非典型性到明显恶性不等。3 名患者死于疾病,2 名患者存活且无疾病证据。
恶性甲状腺畸胎瘤是一种罕见的实体瘤,与甲状腺其他高级别肿瘤有细胞形态学重叠。最近的分子研究已经确定了恶性甲状腺畸胎瘤中反复出现的 DICER1 突变,并提出这些突变是一种独特的临床病理实体。这里描述的特征可能有助于提供正确的前瞻性解释。